AstraZeneca asthma drug gets priority FDA review
AstraZeneca
11,394.00p
09:00 24/04/24
1.12%
126.00p
AstraZeneca on Thursday said its experimental drug tezepelumab had been given a priority review by the US Food and Drug Administration for potential approval as a treatment for asthma.
FTSE 100
8,079.87
09:00 24/04/24
n/a
n/a
FTSE 350
4,441.07
09:00 24/04/24
n/a
n/a
FTSE All-Share
4,395.07
09:00 24/04/24
n/a
n/a
Pharmaceuticals & Biotechnology
22,057.10
09:00 24/04/24
0.87%
191.02
The medicine, developed in conjunction with US-based Amgen, showed in trials it can reduce asthma attacks in patients with severe and uncontrolled forms of the respiratory condition.
A decision is expected in the first quarter of 2022, the company said on Thursday.